Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065325 · ClinicalTrials.gov registry record · Phase 3
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 694
- Enrollment target
NCT00065325 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 694 participants.
The verdict
NCT00065325, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 694 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.
Interventions
- DRUG Exemestane
- DRUG Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 694 participants |
| Start Date | 2003-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065325
The ClinicalTrials.gov registry entry for NCT00065325 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 694 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exemestane is the first listed.
NCT00065325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065325 about?
NCT00065325 is a clinical study titled "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer". The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in ...
What is the current status of trial NCT00065325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 694 participants. The study started on 2003-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00065325?
The interventions under investigation include: Exemestane (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT00065325?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.